Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, generic drugs, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and… Read more
Fuan Pharmaceutical Group Co (300194) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.51 Billion CNY
Based on the latest financial reports, Fuan Pharmaceutical Group Co (300194) has total liabilities worth CN¥1.51 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fuan Pharmaceutical Group Co - Total Liabilities Trend (2007–2024)
This chart illustrates how Fuan Pharmaceutical Group Co's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fuan Pharmaceutical Group Co Competitors by Total Liabilities
The table below lists competitors of Fuan Pharmaceutical Group Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
China | CN¥2.76 Billion |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥1.49 Billion |
|
Hagerty Inc
NYSE:HGTY
|
USA | $1.44 Billion |
|
momo.com Inc
TW:8454
|
Taiwan | NT$17.26 Billion |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
Brazil | R$30.65 Billion |
|
NMDC Steel Limited
NSE:NSLNISP
|
India | ₹148.55 Billion |
|
Hippo Holdings Inc
NYSE:HIPO
|
USA | $1.45 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Fuan Pharmaceutical Group Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fuan Pharmaceutical Group Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fuan Pharmaceutical Group Co (2007–2024)
The table below shows the annual total liabilities of Fuan Pharmaceutical Group Co from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.58 Billion | -13.50% |
| 2023-12-31 | CN¥1.83 Billion | -5.40% |
| 2022-12-31 | CN¥1.93 Billion | +4.94% |
| 2021-12-31 | CN¥1.84 Billion | +29.83% |
| 2020-12-31 | CN¥1.42 Billion | +89.89% |
| 2019-12-31 | CN¥746.59 Million | +24.72% |
| 2018-12-31 | CN¥598.62 Million | +15.51% |
| 2017-12-31 | CN¥518.24 Million | +19.41% |
| 2016-12-31 | CN¥434.00 Million | +26.56% |
| 2015-12-31 | CN¥342.91 Million | +175.02% |
| 2014-12-31 | CN¥124.69 Million | -9.95% |
| 2013-12-31 | CN¥138.47 Million | +64.44% |
| 2012-12-31 | CN¥84.20 Million | -32.47% |
| 2011-12-31 | CN¥124.69 Million | +91.57% |
| 2010-12-31 | CN¥65.09 Million | -41.00% |
| 2009-12-31 | CN¥110.31 Million | +20.13% |
| 2008-12-31 | CN¥91.83 Million | +26.53% |
| 2007-12-31 | CN¥72.58 Million | -- |